Skip to main content
. Author manuscript; available in PMC: 2021 Jul 21.
Published in final edited form as: Breast Cancer Res Treat. 2020 Sep 13;185(1):1–12. doi: 10.1007/s10549-020-05917-7

Table 2.

T stage, nodal status, and pathologic complete response in 85 triple-negative breast cancer patients and the subsets of patients with or without necrotic carcinomas

Characteristic Study population (n = 85) Necrotic carcinomas (n = 39) Non-necrotic carcinomas (n = 46) P-value
T stage 0.07
T1 14/85 (16) 3/39 (8) 11/46 (24)
T2 44/85 (52) 20/39 (51) 24/46 (52)
T3 27/85 (32) 16/39 (41) 11/46 (24)
Nodal status at staging 0.69
Positive 46/85 (54) 22/39 (56) 24/46 (52)
Negative 39/85 (46) 17/39 (44) 22/46 (48)
Nodal status at surgery 0.75
Positive 21/85 (25) 9/39 (23) 12/46 (26)
Negative 64/85 (75) 30/39 (77) 34/46 (74)
pCR status 0.99
pCR 37/85 (44) 17/39 (44) 20/46 (43)
Non-pCR 48/85 (56) 22/39 (56) 26/46 (57)

Data are number of patients (percent) with the exception of the P-value column. P-values comparing characteristic distributions between necrotic and non-necrotic patients used Chi-square test

pCR pathological complete response